Our Portfolio

CellSonic develops non-invasive bioelectric shockwave devices to stimulate cell repair, wound healing, and cancer treatment without drugs or surgery.

Codetta Bio develops integrated multiplexed assays combining DNA, RNA, and protein detection to enable comprehensive, high-throughput molecular diagnostics and precision medicine.

Enrich Biosystems develops advanced cell isolation and enrichment technologies that improve recovery, purity, and viability for single-cell and proteomic applications.

Fluent Bio was acquired by Illumina in 2024 for single-cell technology integration.

Fluent Bio enables high-throughput single-cell RNA sequencing using scalable, instrument-free barcoding technology.

Intus Bio develops molecular diagnostic tools and point-of-care platforms to enable rapid, accessible detection of infectious and genetic diseases.

ProteoWise revolutionizes proteomics with HyperBlot, an automated multiplexed platform delivering rapid, quantitative protein analysis.

Talee Bio merged with Spirovant Sciences in 2017 under ReGenXBio.

Talee Bio developed AAV gene therapies for cystic fibrosis before merging into Spirovant Sciences, now owned by Sumitomo Dainippon Pharma.

Tangen Biosciences develops rapid, portable molecular diagnostic systems using isothermal amplification to detect infectious diseases at the point of care.

10x Genomics IPO’d in 2019 on Nasdaq under ticker TXG.

10x Genomics develops single-cell and spatial biology tools that enable high-resolution molecular profiling for biomedical research and discovery.

Bactana was acquired by Kemin Industries in May of 2025.
They were a Cornell University spinoff at the forefront of anaerobic fermentation and the isolation of postbiotic molecules produced by commensal bacteria in the microbiome.

address prostate, hormone, fertility and sexual health.
Bastion Health - Men's Digital Clinic

Encapsulate Bio develops a patient-on-a-chip system that grows mini tumors to test cancer drugs and personalize treatment decisions.